Pfizer, Mylan Await Decision In Norvasc Patent Case

Law360, New York (December 7, 2006, 12:00 AM EST) -- After a seven-day bench trial, attorneys for Pfizer Inc. and generic drug maker Mylan Pharmaceuticals Inc. made closing arguments Wednesday, putting the final touch on a longstanding patent infringement suit over Pfizer’s blockbuster drug Norvasc.

Now that the trial before Judge Terrence F. McVerry of the U.S. District Court

Western District of Pennsylvania has wrapped up, both parties await a decision as to whether or not Mylan can sell a generic version of Norvasc.

Pfizer received Norvasc’s patent in 1987, and it is set to expire...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.